@conference{845d9f40489248db94206e0bcc257b17,
title = "Quality of life in patients with pure and mixed anaplastic oligodendroglioma treated with dose-intense temozolomide: A phase II multicenter study.",
author = "Sadraei, \{N. Hashemi\} and Ahluwalia, \{M. S.\} and C. Brewer and D. Schiff and Fisher, \{P. G.\} and Chamberlain, \{M. C.\} and S. Panullo and Newton, \{H. B.\} and P. Elson and D. Peereboom",
note = "2080 Background: Treatment options for patients with newly diagnosed pure and mixed anaplastic oligodendrogliomas (AO and MAO, respectively) include chemotherapy (CXT), radiation therapy (RT), or combined CXT and RT. Due to concerns about radiation-induced toxicities, we conducted a multicenter phase II trial using dose-intense temozolomide (TMZ) with delayed RT in AO/MAO.; Journal of Clinical Oncology ; Conference date: 01-01-2020",
year = "2010",
month = may,
day = "20",
doi = "10.1200/JCO.2010.28.15\_SUPPL.2080",
language = "American English",
}